StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) stock

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3025% above fair value
$1415.55−16.12 (-1.13%)

Close on Nov 17, 2026Market cap $1.33TP/E 45.9Yield 0.44%

Eli Lilly operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Eli Lilly's operating cash flow for the twelve months ending Sep 30, 2026 was $30.65B, up 90.8% year over year. For fiscal 2025 it was $16.81B, up 90.7% from the year before. Over ten years it grew 19.0% a year on average. The highest annual figure on record is $16.81B in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$16.81B+90.7%
FY2024Dec 31, 2024$8.82B+108.0%
FY2023Dec 31, 2023$4.24B-44.1%
FY2022Dec 31, 2022$7.59B+3.0%
FY2021Dec 31, 2021$7.37B+13.3%
FY2020Dec 31, 2020$6.50B+34.4%
FY2019Dec 31, 2019$4.84B-12.5%
FY2018Dec 31, 2018$5.52B-1.6%
FY2017Dec 31, 2017$5.62B+15.8%
FY2016Dec 31, 2016$4.85B+63.6%
FY2015Dec 31, 2015$2.96B-33.5%
FY2014Dec 31, 2014$4.46B-22.3%
FY2013Dec 31, 2013$5.74B+8.1%
FY2012Dec 31, 2012$5.30B-26.7%
FY2011Dec 31, 2011$7.23B+5.5%
FY2010Dec 31, 2010$6.86B+58.2%
FY2009Dec 31, 2009$4.34B-40.6%
FY2008Dec 31, 2008$7.30B+41.5%
FY2007Dec 31, 2007$5.15B–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$11.40B+29.0%
Q2 FY2026Jun 30, 2026$10.69B+246.3%
Q1 FY2026Mar 31, 2026$5.33B+220.1%
Q4 FY2025Dec 31, 2025$3.23B+30.4%
Q3 FY2025Sep 30, 2025$8.84B+138.0%
Q2 FY2025Jun 30, 2025$3.09B+110.5%
Q1 FY2025Mar 31, 2025$1.67B+42.9%
Q4 FY2024Dec 31, 2024$2.47B–
Q3 FY2024Sep 30, 2024$3.71B+69.5%
Q2 FY2024Jun 30, 2024$1.47B+132.0%
Q1 FY2024Mar 31, 2024$1.17B-32.6%
Q4 FY2023Dec 31, 2023-$312.00M-118.8%
Q3 FY2023Sep 30, 2023$2.19B-1.2%
Q2 FY2023Jun 30, 2023$631.90M-46.6%
Q1 FY2023Mar 31, 2023$1.73B-31.4%
Q4 FY2022Dec 31, 2022$1.66B-26.5%
Q3 FY2022Sep 30, 2022$2.22B+35.9%
Q2 FY2022Jun 30, 2022$1.18B-33.4%
Q1 FY2022Mar 31, 2022$2.52B+48.6%
Q4 FY2021Dec 31, 2021$2.26B+24.6%
Q3 FY2021Sep 30, 2021$1.63B-9.7%
Q2 FY2021Jun 30, 2021$1.78B-28.8%
Q1 FY2021Mar 31, 2021$1.70B+343.9%
Q4 FY2020Dec 31, 2020$1.82B-7.6%
Q3 FY2020Sep 30, 2020$1.81B+19.6%
Q2 FY2020Jun 30, 2020$2.50B+137.3%
Q1 FY2020Mar 31, 2020$382.40M+22.8%
Q4 FY2019Dec 31, 2019$1.96B+35.5%
Q3 FY2019Sep 30, 2019$1.51B-28.8%
Q2 FY2019Jun 30, 2019$1.05B-30.7%
Q1 FY2019Mar 31, 2019$311.30M-28.7%
Q4 FY2018Dec 31, 2018$1.45B-16.9%
Q3 FY2018Sep 30, 2018$2.12B+12.8%
Q2 FY2018Jun 30, 2018$1.52B-8.1%
Q1 FY2018Mar 31, 2018$436.50M+28.4%
Q4 FY2017Dec 31, 2017$1.74B-13.1%
Q3 FY2017Sep 30, 2017$1.88B–
Q2 FY2017Jun 30, 2017$1.65B–
Q1 FY2017Mar 31, 2017$339.90M–
Q4 FY2016Dec 31, 2016$2.01B–

More Eli Lilly figures

See a number that looks wrong?